HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogues therapy

作     者：Michele Barone Andrea Iannone Alfredo Di Leo 

作者机构：Gastroenterology UnitDepartment of Medical and Surgical ScienceUniversity of Foggia Gastroenterology UnitDepartment of Emergency and Organ Transplantation (D.E.T.O.)University of Bari 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2014年第20卷第26期

页      面：8722-8725页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Addition HBeAg negative HBsAg clearance Nucleos(t) 

摘      要：The ideal endpoint of hepatitis B virus(HBV)antiviral therapy is HBsAg loss,a difficult goal to obtain,especially in HBeAg negative ***,we report the results obtained by the addition of peg-interferonα-2a to a long-lasting nucleos(t)ide analogues therapy in a HBeAg negative,genotype D patient with steadily HBV-DNA negative/HBsAg positive *** 2002,our Caucasian 44-year-old male patient received lamivudine and,4 years later,added adefovir because of a virological *** 2011,considering his young age,liver stiffness(4.3 kPa)and HBsAg levels(3533IU/mL),we added Peg-interferonα-2a for six months(3in combination with nucleos(t)ide analogues followed by 3 mo of Peg-interferonα-2a monotherapy).A decrease of HBsAg levels was observed after 1 mo(1.21log)of Peg-interferon and 3 mo(1.88 log)after the discontinuation of all ***,a complete clearance of HBsAg was obtained with steadily undetectable HBVDNA serum levels(9 IU/mL).HBsAg clearance by the addition of a short course of Peg-interferonα-2a represents an important result with clinical and pharmacoeconomic implications,considering that nucleos(t)ide analogues therapy in HBeAg negative chronic hepatitis B patients is considered a long-lasting/life-long treatment.